Recurrent Malignant Glioma Clinical Trials
29 clinical trials for Recurrent Malignant Glioma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors — RECRUITING · PHASE1
- MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma — RECRUITING · PHASE1
- Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas — RECRUITING · PHASE1
- Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial — ACTIVE_NOT_RECRUITING · PHASE2
- Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors — ACTIVE_NOT_RECRUITING · PHASE1
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma — ACTIVE_NOT_RECRUITING · PHASE1
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial — ACTIVE_NOT_RECRUITING · PHASE2
- Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
- Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma — ACTIVE_NOT_RECRUITING · PHASE1
- Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
- Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
- Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
- Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults — ACTIVE_NOT_RECRUITING · PHASE1
- Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas — ACTIVE_NOT_RECRUITING · PHASE1
- Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
- Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
- IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma — NOT_YET_RECRUITING · PHASE1
- Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas — ACTIVE_NOT_RECRUITING
- Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype — ACTIVE_NOT_RECRUITING · NA
- Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) — TERMINATED · PHASE1
- Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma — ACTIVE_NOT_RECRUITING · PHASE1
- Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma — COMPLETED · PHASE2
- Fimepinostat in Treating Brain Tumors in Children and Young Adults — ACTIVE_NOT_RECRUITING · PHASE1
- Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer — WITHDRAWN · PHASE1
- Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients — OTHER · PHASE1
- A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) — OTHER · PHASE1
- STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain — COMPLETED · PHASE1
- Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma — WITHDRAWN · PHASE1
- Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma — OTHER · PHASE2
Refine this search